SCHEMBL864263

SCHEMBL864263

O=C(O)N(Cc1ccccc1)Cc1nnc(-c2ccc(OCc3ccccc3)cc2)o1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.54
LMNA P02545 3/20 0.54
GAA P10253 2/20 0.54
HTT P42858 2/20 0.54
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
SMN1; SMN2 Q16637 4/20 0.53
ALDH1A1 P00352 3/20 0.53
POLB P06746 3/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
MAPT P10636 2/20 0.51
NPSR1 Q6W5P4 1/20 0.49
TP53 P04637 1/20 0.48
TSHR P16473 2/20 0.47
ALOX5 P09917 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12473336 0.80 HDAC8 (0.57) HPGDLMNAGAAHTTCASP3
SCHEMBL29241778 0.79 ALDH1A1 (0.65) HPGDLMNAGAAHTTCASP3
SCHEMBL863481 0.79 NOTUM (0.65) HPGDLMNAGAAHTTCASP3
SCHEMBL12171570 0.78 NR4A2 (0.70) HPGDLMNAGAAHTTCASP3
SCHEMBL8281630 0.78 MAPT (0.69) HPGDLMNAGAAHTTCASP3
SCHEMBL15080649 0.76 HDAC8 (0.53) HPGDLMNAGAAHTTCASP3
SCHEMBL863405 0.75 MGAM (0.56) GAASMN1; SMN2POLBNPC1RAB9A
SCHEMBL29032391 0.73 KDM4E (0.64) HPGDLMNAGAAHTTCASP3
SCHEMBL12171443 0.73 RAB9A (0.67) HPGDLMNAGAAHTTCASP3
SCHEMBL29241751 0.73 SMN1; SMN2 (0.51) HPGDLMNAGAAHTTCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077847-A1 ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077847-A1 ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS LIPG, LIPA, LIPE HPGD 791/4885LMNA 510/4885GAA 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.